Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 109 articles:
HTML format



Single Articles


    May 2021
  1. ARROYO MUHR LS, Hultin E, Dillner J
    Transcription of Human Papillomaviruses in Non-Melanoma Skin Cancers of the Immunosuppressed.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33683.
    PubMed     Abstract available


    April 2021
  2. SUN Q, Novak D, Huser L, Poelchen J, et al
    FOXD1 Promotes Dedifferentiation and Targeted Therapy Resistance in Melanoma by Regulating the Expression of CTGF.
    Int J Cancer. 2021 Apr 9. doi: 10.1002/ijc.33591.
    PubMed     Abstract available


    February 2021
  3. BUCCHI L, Mancini S, Crocetti E, Dal Maso L, et al
    Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy.
    Int J Cancer. 2021;148:835-844.
    PubMed     Abstract available


    January 2021
  4. SACCHETTO L, Rosso S, Comber H, Bouchardy C, et al
    Skin Melanoma Deaths Within 1 Or 3 Years From Diagnosis In Europe.
    Int J Cancer. 2021 Jan 26. doi: 10.1002/ijc.33479.
    PubMed     Abstract available


  5. MONESTIER S, Dalle S, Mortier L, Dutriaux C, et al
    Effectiveness and Safety of Nivolumab in Patients with Advanced Melanoma: A Multicenter, Observational Study.
    Int J Cancer. 2021 Jan 11. doi: 10.1002/ijc.33467.
    PubMed     Abstract available


    December 2020
  6. CHOI J, Jia G, Wen W, Long J, et al
    Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants.
    Int J Cancer. 2020;147:3416-3423.
    PubMed     Abstract available


    November 2020
  7. DELLAC S, Ben-Dov H, Raanan A, Saleem H, et al
    Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33401.
    PubMed     Abstract available


    October 2020
  8. DAI WF, Beca J, Croxford R, Isaranuwatchai W, et al
    Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33357.
    PubMed     Abstract available


    September 2020
  9. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    PubMed     Abstract available


    August 2020
  10. BOARD R, Smittenaar R, Lawton S, Liu H, et al
    Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
    Int J Cancer. 2020 Aug 24. doi: 10.1002/ijc.33266.
    PubMed     Abstract available


  11. SATO M, Onuma K, Domon M, Hasegawa S, et al
    Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and dramatically increases survival rates of mice.
    Int J Cancer. 2020 Aug 20. doi: 10.1002/ijc.33262.
    PubMed     Abstract available


  12. MENGONI M, Braun AD, Gaffal E, Tuting T, et al
    The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells.
    Int J Cancer. 2020 Aug 13. doi: 10.1002/ijc.33252.
    PubMed     Abstract available


    July 2020
  13. WANG X, Yu B, Cao B, Zhou J, et al
    A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33222.
    PubMed     Abstract available


    June 2020
  14. VAN ZEIJL MCT, Ismail RK, de Wreede LC, van den Eertwegh AJM, et al
    Real-world outcomes of advanced melanoma patients not represented in phase III trials.
    Int J Cancer. 2020 Jun 19. doi: 10.1002/ijc.33162.
    PubMed     Abstract available


    May 2020
  15. HE Q, Li X, He L, Li Y, et al
    Pericyte dysfunction due to Shb gene deficiency increases B16F10 melanoma lung metastasis.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33110.
    PubMed     Abstract available


    April 2020
  16. ROBINSON SN, Zens MS, Rees JR, Barton DT, et al
    Risk of Melanoma Following Keratinocyte Malignancies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33011.
    PubMed     Abstract available


  17. TSENG HY, Dreyer J, Al Emran A, Gunatilake D, et al
    Co-targeting BET proteins and MCL1 induces synergistic cell death in melanoma.
    Int J Cancer. 2020 Apr 5. doi: 10.1002/ijc.33000.
    PubMed     Abstract available


    February 2020
  18. FUNCK-BRENTANO E, Baghad B, Fort M, Aouidad I, et al
    Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
    Int J Cancer. 2020 Feb 21. doi: 10.1002/ijc.32934.
    PubMed     Abstract available


  19. BAADE PD, Whiteman DC, Janda M, Cust AE, et al
    Long-Term Deaths From Melanoma According To Tumour Thickness At Diagnosis.
    Int J Cancer. 2020 Feb 17. doi: 10.1002/ijc.32930.
    PubMed     Abstract available


  20. ISLAMI F, Sauer AG, Miller KD, Fedewa SA, et al
    Cutaneous melanomas attributable to ultraviolet radiation exposure by state.
    Int J Cancer. 2020 Feb 17. doi: 10.1002/ijc.32921.
    PubMed     Abstract available


    November 2019
  21. BASSAN D, Gozlan YM, Sharbi-Yunger A, Tzehoval E, et al
    Optimizing T-cell receptor avidity with somatic hypermutation.
    Int J Cancer. 2019;145:2816-2826.
    PubMed     Abstract available


  22. BELLMANN L, Cappellano G, Schachtl-Riess JF, Prokopi A, et al
    A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Int J Cancer. 2019 Nov 8. doi: 10.1002/ijc.32777.
    PubMed     Abstract available


    October 2019
  23. WU Y, Wang Y, Wang L, Yin P, et al
    Burden of Melanoma in China, 1990-2017: Findings from the 2017 Global Burden of Disease Study.
    Int J Cancer. 2019 Oct 31. doi: 10.1002/ijc.32764.
    PubMed     Abstract available


  24. ZHOU Y, Huang Z, Su J, Li J, et al
    Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment.
    Int J Cancer. 2019 Oct 25. doi: 10.1002/ijc.32756.
    PubMed     Abstract available


  25. VAN OPIJNEN MP, Dirven L, Coremans IEM, Taphoorn MJB, et al
    The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: a systematic review.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32696.
    PubMed     Abstract available


  26. KOSKE I, Rossler A, Pipperger L, Petersson M, et al
    Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Int J Cancer. 2019;145:1958-1969.
    PubMed     Abstract available


  27. LI Z, Zhou J, Zhang J, Li S, et al
    Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.
    Int J Cancer. 2019;145:1946-1957.
    PubMed     Abstract available


    September 2019
  28. CERVENKA I, Al Rahmoun M, Mahamat-Saleh Y, Fournier A, et al
    Exogenous Hormone Use and Cutaneous Melanoma Risk in Women: The European Prospective Investigation Into Cancer and Nutrition.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32674.
    PubMed     Abstract available


  29. DRAGHI A, Borch TH, Radic HD, Chamberlain CA, et al
    Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs.
    Int J Cancer. 2019;145:1408-1413.
    PubMed     Abstract available


  30. IRENAEUS SMM, Nielsen D, Ellmark P, Yachnin J, et al
    First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.
    Int J Cancer. 2019;145:1189-1199.
    PubMed     Abstract available


    August 2019
  31. BRUSCO I, Li Puma S, Chiepe KB, da Silva Brum E, et al
    Dacarbazine alone or associated with melanoma-bearing cancer pain model induces painful hypersensitivity by TRPA1 activation in mice.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32648.
    PubMed     Abstract available


  32. ELLEBAEK E, Bastholt L, Schmidt H, Svane IM, et al
    The real-world outcome of metastatic melanoma: unknown primary versus known cutaneous.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32631.
    PubMed    


  33. VERVER D, van der Veldt A, van Akkooi A, Verhoef C, et al
    Reply to: The real-world outcome of metastatic melanoma: unknown primary versus known cutaneous.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32630.
    PubMed    


  34. TURNER MC, Gracia-Lavedan E, Cirac M, Castano-Vinyals G, et al
    Reply to: Air pollution and incident bladder cancer: a risk assessment.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32632.
    PubMed    


  35. FURFARO AL, Ottonello S, Loi G, Cossu I, et al
    HO-1 downregulation favors BRAF(V600) melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition.
    Int J Cancer. 2019 Aug 3. doi: 10.1002/ijc.32611.
    PubMed     Abstract available


    July 2019
  36. KINOSHITA R, Sato H, Yamauchi A, Takahashi Y, et al
    Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.
    Int J Cancer. 2019;145:569-575.
    PubMed     Abstract available


    June 2019
  37. GENER LAHAV T, Adler O, Zait Y, Shani O, et al
    Melanoma-derived extracellular vesicles instigate pro-inflammatory signaling in the metastatic microenvironment.
    Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32521.
    PubMed     Abstract available


  38. KINOSHITA R, Sato H, Yamauchi A, Takahashi Y, et al
    exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.
    Int J Cancer. 2019;144:3138-3145.
    PubMed     Abstract available


    May 2019
  39. OROUJI E, Federico A, Larribere L, Novak D, et al
    Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
    Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32432.
    PubMed     Abstract available


    March 2019
  40. MOREIRA A, Gross S, Kirchberger MC, Erdmann M, et al
    Senescence markers: Predictive for response to checkpoint inhibitors.
    Int J Cancer. 2019;144:1147-1150.
    PubMed     Abstract available


    February 2019
  41. VERVER D, van der Veldt A, van Akkooi A, Verhoef C, et al
    Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study.
    Int J Cancer. 2019 Feb 23. doi: 10.1002/ijc.32229.
    PubMed     Abstract available


  42. DAI W, Liu H, Xu X, Jie G, et al
    Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival.
    Int J Cancer. 2019 Feb 8. doi: 10.1002/ijc.32194.
    PubMed     Abstract available


    January 2019
  43. FRANKE V, Berger DMS, Klop WMC, van der Hiel B, et al
    High Response Rates for T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a).
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32172.
    PubMed     Abstract available


  44. CERVENKA I, Al Rahmoun M, Mahamat Saleh Y, Savoye I, et al
    Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32150.
    PubMed     Abstract available


  45. ANTONIAZZI CTD, Nassini R, Rigo FK, Milioli AM, et al
    Transient receptor potential ankyrin 1 (TRPA1) plays a critical role in a mouse model of cancer pain.
    Int J Cancer. 2019;144:355-365.
    PubMed     Abstract available


    December 2018
  46. WEIDELE K, Stojanovic N, Feliciello G, Markiewicz A, et al
    Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32092.
    PubMed     Abstract available


  47. GUO D, Lui GYL, Lai SL, Wilmott JS, et al
    RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.
    Int J Cancer. 2018 Dec 17. doi: 10.1002/ijc.32064.
    PubMed     Abstract available


    November 2018
  48. RUEEGG CS, Stenehjem JS, Egger M, Ghiasvand R, et al
    Challenges in Assessing the Sunscreen-Melanoma Association.
    Int J Cancer. 2018 Nov 16. doi: 10.1002/ijc.31997.
    PubMed     Abstract available


  49. POTJER TP, Bollen S, Grimbergen AJEM, van Doorn R, et al
    Multi-gene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Int J Cancer. 2018 Nov 10. doi: 10.1002/ijc.31984.
    PubMed     Abstract available


    September 2018
  50. DASSLER-PLENKER J, Paschen A, Putschli B, Rattay S, et al
    Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity towards autologous melanoma cells.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31874.
    PubMed     Abstract available


  51. BRADBURY KE, Appleby PN, Tipper SJ, Travis RC, et al
    Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31854.
    PubMed     Abstract available


  52. WILMOTT JS, Johansson PA, Newell F, Waddell N, et al
    Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.
    Int J Cancer. 2018 Sep 4. doi: 10.1002/ijc.31791.
    PubMed     Abstract available


  53. MAEDA T, Hayashi T, Furukawa H, Iwasaki D, et al
    Immune-mediated antitumor effect of a transplanted lymph node.
    Int J Cancer. 2018;143:1224-1235.
    PubMed     Abstract available


    August 2018
  54. ZHAO B, Zhao H, Zhao J
    Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31813.
    PubMed     Abstract available


  55. WU H, Larribere L, Sun Q, Novak D, et al
    Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31799.
    PubMed     Abstract available


  56. SHARBI-YUNGER A, Grees M, Gal C, Bassan D, et al
    A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Int J Cancer. 2018 Aug 14. doi: 10.1002/ijc.31795.
    PubMed     Abstract available


  57. ANDRES-LENCINA JJ, Rachakonda S, Garcia-Casado Z, Srinivas N, et al
    TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31780.
    PubMed     Abstract available


  58. BIALKOWSKI L, Van der Jeught K, Bevers S, Tjok Joe P, et al
    Immune checkpoint blockade combined with IL-6 and TGF-beta inhibition improves the therapeutic outcome of mRNA-based immunotherapy.
    Int J Cancer. 2018;143:686-698.
    PubMed     Abstract available


    July 2018
  59. IZRAELY S, Ben-Menachem S, Sagi-Assif O, Telerman A, et al
    The Metastatic Microenvironment: Melanoma-Microglia Cross-Talk Promotes the Malignant Phenotype of Melanoma Cells.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31745.
    PubMed     Abstract available


  60. YANG CC, Chang CK, Chang MT, Shyur LF, et al
    Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-alpha-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31663.
    PubMed     Abstract available


  61. CERVENKA I, Mahamat-Saleh Y, Savoye I, Dartois L, et al
    Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31644.
    PubMed     Abstract available


  62. WU Y, Ju Q, Jia K, Yu J, et al
    Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Int J Cancer. 2018;143:45-51.
    PubMed     Abstract available


    June 2018
  63. HUSER L, Sachindra, Granados K, Federico A, et al
    SOX2-mediated upregulation of CD24 promotes adaptive resistance towards targeted therapy in melanoma.
    Int J Cancer. 2018 Jun 15. doi: 10.1002/ijc.31609.
    PubMed     Abstract available


    May 2018
  64. HUANG X, Yang Y, Zhao Y, Cao D, et al
    RhoA-stimulated intra-capillary morphology switch facilitates the arrest of individual circulating tumor cells.
    Int J Cancer. 2018;142:2094-2105.
    PubMed     Abstract available


  65. LI Y, Fan Y, Xu J, Zhang P, et al
    Genome-wide RNA-Seq identifies Fas/FasL-mediated tumoricidal activity of embryonic stem cells.
    Int J Cancer. 2018;142:1829-1841.
    PubMed     Abstract available


    April 2018
  66. ARNOLD M, de Vries E, Whiteman DC, Jemal A, et al
    Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31527.
    PubMed     Abstract available


    March 2018
  67. CALLAHAN BM, Patel JS, Fawcett TJ, Blanck G, et al
    Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir.
    Int J Cancer. 2018;142:988-998.
    PubMed     Abstract available


    February 2018
  68. CZARNECKI D
    Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31348.
    PubMed    


  69. AITKEN JF, Youlden DR, Baade PD, Soyer HP, et al
    In response to: Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31347.
    PubMed    


  70. LIYANAGE UE, Law MH, Ong JS, Cust AE, et al
    Polyunsaturated fatty acids and risk of melanoma: A Mendelian randomisation analysis.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31334.
    PubMed     Abstract available


    January 2018
  71. LI B, Wang Y, Xu Y, Liu H, et al
    Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival.
    Int J Cancer. 2018 Jan 4. doi: 10.1002/ijc.31243.
    PubMed     Abstract available


  72. FAURE F, Jouve M, Lebhar-Peguillet I, Sadaka C, et al
    Blood monocytes sample MelanA/MART1 antigen for long-lasting cross-presentation to CD8(+) T cells after differentiation into dendritic cells.
    Int J Cancer. 2018;142:133-144.
    PubMed     Abstract available


    December 2017
  73. WU Y, Shi H, Jiang M, Qiu M, et al
    The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Int J Cancer. 2017;141:2562-2570.
    PubMed     Abstract available


  74. MARTIN CA, Cullinane C, Kirby L, Abuhammad S, et al
    Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance.
    Int J Cancer. 2017 Dec 15. doi: 10.1002/ijc.31220.
    PubMed     Abstract available


  75. GALLAGHER SJ, Gunatilake D, Beaumont KA, Sharp DM, et al
    HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31199.
    PubMed     Abstract available


  76. HUANG L, Qin Y, Zuo Q, Bhatnagar K, et al
    Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31196.
    PubMed     Abstract available


    November 2017
  77. CHEN ST, Li X, Han J
    Personal history of non-melanoma skin cancer diagnosis and death from melanoma in women.
    Int J Cancer. 2017 Nov 24. doi: 10.1002/ijc.31176.
    PubMed     Abstract available


  78. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Reply to prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 20. doi: 10.1002/ijc.31162.
    PubMed    


  79. KAWADA T
    Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 18. doi: 10.1002/ijc.31163.
    PubMed    


  80. AITKEN JF, Youlden DR, Baade PD, Soyer HP, et al
    Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014.
    Int J Cancer. 2017 Nov 6. doi: 10.1002/ijc.31141.
    PubMed     Abstract available


    October 2017
  81. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and cutaneous melanoma: Prospective data from the population-based Janus Cohort.
    Int J Cancer. 2017 Oct 6. doi: 10.1002/ijc.31086.
    PubMed     Abstract available


  82. SANTOS JM, Havunen R, Siurala M, Cervera-Carrascon V, et al
    Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
    Int J Cancer. 2017;141:1458-1468.
    PubMed     Abstract available


    September 2017
  83. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Sentinel Lymph Node Biopsy vs Observation in Thick Melanoma: A Multicenter Propensity Score Matching Study.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31078.
    PubMed     Abstract available


  84. GABELLINI C, Gomez-Abenza E, Ibanez-Molero S, Tupone MG, et al
    Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model.
    Int J Cancer. 2017 Sep 26. doi: 10.1002/ijc.31075.
    PubMed     Abstract available


  85. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    PubMed     Abstract available


    August 2017
  86. UTJES D, Lyth J, Lapins J, Eriksson H, et al
    Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas - a nationwide, population-based study.
    Int J Cancer. 2017 Aug 11. doi: 10.1002/ijc.30925.
    PubMed     Abstract available


    July 2017
  87. BOTTERI E, Stoer NC, Sakshaug S, Graff-Iversen S, et al
    Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
    Int J Cancer. 2017 Jul 7. doi: 10.1002/ijc.30878.
    PubMed     Abstract available


  88. KOU Y, Ji L, Wang H, Wang W, et al
    Connexin 43 Upregulation by Dioscin Inhibits Melanoma Progression via Suppressing Malignancy and Inducing M1 Polarization.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30872.
    PubMed     Abstract available


    June 2017
  89. GORDON D, Hansson J, Eloranta S, Gordon M, et al
    Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma.
    Int J Cancer. 2017 Jun 20. doi: 10.1002/ijc.30843.
    PubMed     Abstract available


  90. LAURENZANA A, Chilla A, Luciani C, Peppicelli S, et al
    uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.
    Int J Cancer. 2017 Jun 2. doi: 10.1002/ijc.30817.
    PubMed     Abstract available


  91. TU YN, Tong WL, Samy MD, Yavorski JM, et al
    Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-alpha/beta V(D)J recombinations correlates with PD-1 expression.
    Int J Cancer. 2017;140:2568-2576.
    PubMed     Abstract available


    May 2017
  92. LI X, Liu H, Amos CI, Lee JE, et al
    A PGC1beta genetic variant associated with nevus count and melanoma mortality.
    Int J Cancer. 2017 May 23. doi: 10.1002/ijc.30802.
    PubMed    


  93. LIU S, Wang Y, Xue W, Liu H, et al
    Genetic Variants in the Genes Encoding Rho GTPases and Related Regulators Predict Cutaneous Melanoma-specific Survival.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30785.
    PubMed     Abstract available


    March 2017
  94. TANG JQ, Hou XY, Yang CS, Li YX, et al
    Recent developments in nanomedicine for melanoma treatment.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30708.
    PubMed     Abstract available


  95. SHI H, Zhang J, Han X, Li H, et al
    Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression.
    Int J Cancer. 2017;140:1370-1383.
    PubMed     Abstract available


  96. SILVERSMIT G, Jegou D, Vaes E, Van Hoof E, et al
    Cure of cancer for seven cancer sites in the Flemish Region.
    Int J Cancer. 2017;140:1102-1110.
    PubMed     Abstract available


    February 2017
  97. CAINI S, Masala G, Saieva C, Kvaskoff M, et al
    Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2017 Feb 20. doi: 10.1002/ijc.30659.
    PubMed     Abstract available


  98. DE VRIES E, Amador JR, Rincon CJ, Uribe C, et al
    Cutaneous Melanoma Attributable to Solar Radiation in Cali, Colombia.
    Int J Cancer. 2017 Feb 10. doi: 10.1002/ijc.30638.
    PubMed     Abstract available


  99. PARK SM, Li T, Wu S, Li WQ, et al
    Niacin intake and risk of skin cancer in US women and men.
    Int J Cancer. 2017 Feb 2. doi: 10.1002/ijc.30630.
    PubMed     Abstract available


    January 2017
  100. OUDE OPHUIS CM, Louwman MW, Grunhagen DJ, Verhoef C, et al
    Implementation of the 7th Edition AJCC Staging System: Effects on Staging and Survival for pT1 Melanoma. A Dutch Population Based Study.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30607.
    PubMed     Abstract available


  101. POTRONY M, Rebollo-Morell A, Gimenez-Xavier P, Zimmer L, et al
    IRF4 rs12203592 functional variant and melanoma survival.
    Int J Cancer. 2017 Jan 19. doi: 10.1002/ijc.30605.
    PubMed     Abstract available


  102. SIMOES RL, De-Brito NM, Cunha-Costa H, Morandi V, et al
    Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression.
    Int J Cancer. 2017;140:346-357.
    PubMed     Abstract available


    December 2016
  103. SHEN J, Song R, Wan J, Huff C, et al
    Global methylation of blood leukocyte DNA and risk of melanoma.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30577.
    PubMed     Abstract available


  104. BAUM C, Weiss C, Gebhardt C, Utikal J, et al
    Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas.
    Int J Cancer. 2016 Dec 9. doi: 10.1002/ijc.30563.
    PubMed     Abstract available


  105. LI H, Wang Y, Liu H, Shi Q, et al
    Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival.
    Int J Cancer. 2016 Dec 3. doi: 10.1002/ijc.30545.
    PubMed     Abstract available


    November 2016
  106. LAURILA JP, Laukkanen MO, Joensuu H, Salmi M, et al
    Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    Int J Cancer. 2016;139:2270-6.
    PubMed     Abstract available


  107. HEGEDUS L, Garay T, Molnar E, Varga K, et al
    The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.
    Int J Cancer. 2016 Nov 4. doi: 10.1002/ijc.30503.
    PubMed     Abstract available


  108. DESCH A, Gebhardt C, Utikal J, Schneider SW, et al
    D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30498.
    PubMed     Abstract available


    September 2016
  109. SARRABAYROUSE G, Pich C, Teiti I, Tilkin-Mariame AF, et al
    Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30422.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: